IPH.PA
Innate Pharma SA
Price:  
1.53 
EUR
Volume:  
106,269.00
France | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

IPH.PA EV/EBITDA

-342.2%
Upside

As of 2025-07-05, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -3.29. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 153.84 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -46.80 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 1.8x - 6.0x 2.2x
Forward P/E multiples 9.0x - 12.0x 11.8x
Fair Price (4.71) - (3.21) (3.70)
Upside -408.8% - -310.3% -342.2%
1.53 EUR
Stock Price
(3.70) EUR
Fair Price

IPH.PA EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-07-03 -3.28
2025-07-02 -3.28
2025-07-01 -3.30
2025-06-30 -3.28
2025-06-27 -3.35
2025-06-26 -3.33
2025-06-25 -3.26
2025-06-24 -3.24
2025-06-23 -3.30
2025-06-20 -3.41
2025-06-19 -3.53
2025-06-18 -3.56
2025-06-17 -3.52
2025-06-16 -3.55
2025-06-13 -3.61
2025-06-12 -3.66
2025-06-11 -3.73
2025-06-10 -3.80
2025-06-09 -4.00
2025-06-06 -4.06
2025-06-05 -4.06
2025-06-04 -4.08
2025-06-03 -4.11
2025-06-02 -4.09
2025-05-30 -4.17
2025-05-29 -4.19
2025-05-28 -4.14
2025-05-27 -4.06
2025-05-26 -4.15
2025-05-23 -4.15
2025-05-22 -4.16
2025-05-21 -4.13
2025-05-20 -4.14
2025-05-19 -4.10
2025-05-16 -4.06
2025-05-15 -4.06
2025-05-14 -4.13
2025-05-13 -4.20
2025-05-12 -4.24
2025-05-09 -4.31
2025-05-08 -4.37
2025-05-07 -4.26
2025-05-06 -4.07
2025-05-05 -4.04
2025-05-02 -4.16
2025-04-30 -4.09
2025-04-29 -3.91
2025-04-28 -3.88
2025-04-25 -3.74
2025-04-24 -3.75